

IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A method of treating at least one blood circulation disease in a patient in need thereof comprising administering at least one soluble HLA-G isoform to the patient in an amount sufficient to treat the at least one blood circulation disease

~~The use of at least one soluble HLA-G isoform for preparing a medicinal product intended for use in the treatment of blood circulation diseases.~~

Claim 2 (Currently Amended): ~~The use as claimed in~~ The method of claim 1, ~~characterized in that said diseases are~~ wherein the at least one blood circulation disease is selected from the group consisting of anemias and ischemias.

Claim 3 (Currently Amended): A composition comprising at least one soluble HLA-G isoform and at least one pharmaceutically acceptable vehicle

~~The use as claimed in claim 1 or claim 2, characterized in that said soluble HLA-G isoform is in the form of a composition also comprising at least one pharmaceutically acceptable vehicle.~~

Claim 4 (Currently Amended): The composition of Claim 3, wherein the composition is formulated as a liquid

~~The use as claimed in claim 3, characterized in that said composition is in liquid form.~~

Claim 5 (Currently Amended): The composition of Claim 3, wherein the composition is formulated as a solid

~~The use as claimed in claim 3, characterized in that said composition is in solid form.~~

Claim 6 (Currently Amended): A method of detecting and, optionally, sorting cells of the erythrocyte lines, ~~and the endothelial lines~~ lines, or combinations thereof, according to their state of differentiation, comprising ~~characterized in that it comprises:~~

- a) bringing ~~[[the]]~~ a biological sample to be tested into contact with antibodies directed against the following markers: soluble HLA-G isoform, CD71, CD34 and CD45, and
- b) detecting and, optionally, sorting cells corresponding to various stages of differentiation of the erythrocyte lines, ~~[[or]] the endothelial lines, or a combination thereof~~ lines, according to their profile of expression of the markers defined in a).

Claim 7 (Currently Amended): The method as claimed in claim 6, ~~characterized in that it comprises:~~ further comprising

- ~~a) bringing the biological sample to be tested into contact with a panel of antibodies selected from the group consisting of antibodies directed against the following markers: soluble HLA-G isoform, CD71, CD34 and CD45, and~~
- a') selecting the cells expressing the soluble HLA-G isoform, and
- c) detecting the type of cell using the CD71 marker.

Claim 8 (Currently Amended): The method ~~of detection of claim 6 as claimed in claim 6 or claim 7, characterized in that~~ wherein the biological sample is selected from the group consisting of a blood sample ~~[[or]]~~ and a bone marrow sample.

Claim 9 (Currently Amended): The method of claim 6, ~~detection as claimed in any one of claims 6 to 8, characterized in that,~~ wherein prior to ~~step~~ a), the cells of said biological sample are permeabilized.

Claim 10 (New): The method of claim 7, wherein the biological sample is selected from the group consisting of a blood sample and a bone marrow sample.

Claim 11 (New): The method of claim 7, wherein prior to a), the cells of said biological sample are permeabilized.

Claim 12 (New): The method of claim 8, wherein prior to a), the cells of said biological sample are permeabilized.